Atlas Growers Investors

Who We Are

Atlas Growers Ltd. is a wholly owned subsidiary of Atlas Biotechnologies Inc. (collectively together “Atlas”) and was established in 2015 with the objective of being an industry leading producer of cannabis products for medicinal use

Atlas holds a 160-acre land site north-west of Edmonton, Alberta, where our 38,000 square foot, state-of-the-art, custom designed indoor cultivation facility was completed in September 2018. This initial facility is expected to have production capacity of at least 5,000 kg per year of dried cannabis flower and related oil extracts.

Atlas received its initial Cultivation License from Health Canada under the predecessor ACMPR (Access to Cannabis for Medical Purposes Regulations) on October 12, 2018 and a “Business to Business” Sales License on November 15, 2018. Our initial crop was planted in late December 2018.

IT'S A GROWING MARKET

As opposed to many producers applying traditional greenhouse and soil models, we maintain strict controlled-environment production standards which utilize precision instrumentation in gas sealed microclimates to create the highest quality and most consistent cannabis.

Promoting genetic diversity and structured plant breeding are key principles of the Atlas vision. We built a dynamic inventory of cannabis cultivars from across the globe, which will yield our customers an exciting and wide-ranging product line. Produce high grade, consistent, standardized products by leveraging 100% indoor, purpose built, hydroponic growing conditions. We will draw on the extensive indoor horticultural experience of Jim Hole, our VP of Cultivation. Maximize profitability and market value by focusing on premium, high-margin, pharmaceutical applications, rather than the mass produced “commodity” oriented adult-use market.

Develop proprietary intellectual property by investing in a structured plant breeding program which will develop new cultivars and enhance the potential efficacy of certain phytochemicals.

Risk diversification – Atlas has acquired a 20% investment in Flavocure Biotech, Inc., a private US firm with patent applications on new cannabis derived therapeutic drugs being researched for the treatment of acute myeloid leukemia, glioblastoma, and pancreatic cancers.

Atlas plans to expand production capacity outside of the Atlas One facility in order to secure additional supply agreements domestically and overseas. Commit to a broad mix of long-term supply contracts, including annual minimum volume guarantees, with a diversified and stable customer base.